These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Coagulase-negative staphylococci emerging during teicoplanin therapy and the determination of their sensitivity. Jones RN J Antimicrob Chemother; 1992 Jun; 29(6):725-7. PubMed ID: 1387134 [No Abstract] [Full Text] [Related]
44. Susceptibility of gram positive cocci to teicoplanin. Three year survey (1984-1986) at Perugia University. Pasticci MB; Baldelli F; Moretti A; Menichetti F; Pauluzzi S Boll Ist Sieroter Milan; 1989; 68(1):5-6. PubMed ID: 2535245 [TBL] [Abstract][Full Text] [Related]
45. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Santos Sanches I; Mato R; de Lencastre H; Tomasz A; Microb Drug Resist; 2000; 6(3):199-211. PubMed ID: 11144420 [TBL] [Abstract][Full Text] [Related]
46. Comparative in vitro activity of the new peptolide antibiotic LY146032 against staphylococci. Peters G; Schumacher-Perdreau F; Pulverer G Eur J Clin Microbiol; 1987 Dec; 6(6):685. PubMed ID: 2831047 [No Abstract] [Full Text] [Related]
47. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Lin G; Credito K; Ednie LM; Appelbaum PC Antimicrob Agents Chemother; 2005 Feb; 49(2):770-2. PubMed ID: 15673763 [TBL] [Abstract][Full Text] [Related]
48. In-vitro activity of teicoplanin alone and in combination with rifampicin, gentamicin or tobramycin against coagulase-negative staphylococci. Watanakunakorn C J Antimicrob Chemother; 1987 Apr; 19(4):439-43. PubMed ID: 2953706 [TBL] [Abstract][Full Text] [Related]
49. The bactericidal activity of vancomycin and teicoplanin against methicillin-resistant strains of coagulase negative Staphylococcus spp. O'Hare MD; Felmingham D; Grüneberg RN J Antimicrob Chemother; 1989 May; 23(5):800-2. PubMed ID: 2527220 [No Abstract] [Full Text] [Related]
51. The potential impact on clinical practice of differences in the in-vitro activity of vancomycin and teicoplanin. Cheesbrough JS; Smith SR; Davies JM J Antimicrob Chemother; 1990 Apr; 25(4):716-8. PubMed ID: 2141019 [No Abstract] [Full Text] [Related]
52. Detection of staphylococci with reduced susceptibility to glycopeptides. Ferraro MJ; Swenson JM; Tenover FC J Clin Microbiol; 2002 Apr; 40(4):1573. PubMed ID: 11923403 [No Abstract] [Full Text] [Related]
54. [Sensitivity of coagulase positive and negative staphylococci to certain antibiotics]. Moura AO; Cunha WC; Salmito AT Mem Inst Oswaldo Cruz; 1974; 72(1-2):73-9. PubMed ID: 4465639 [No Abstract] [Full Text] [Related]
55. Synthesis and biological activity of some esters of the N-acetylglucosaminyl aglycone and of the aglycone of teicoplanin. Malabarba A; Trani A; Ferrari P; Pallanza R; Cavalleri B J Antibiot (Tokyo); 1987 Nov; 40(11):1572-87. PubMed ID: 2961722 [TBL] [Abstract][Full Text] [Related]
56. Activity of teicoplanin against gram-negative anaerobes. Greenwood D; Palfreyman J; Eley A; Clarry T J Antimicrob Chemother; 1988 Apr; 21(4):500-1. PubMed ID: 2967811 [No Abstract] [Full Text] [Related]
58. [Glycopeptides: mechanism of action and of resistance]. Leclercq R Presse Med; 1999 Apr; 28(13):720-1. PubMed ID: 10228487 [No Abstract] [Full Text] [Related]
59. Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme. Sentry Antimicrobial Surveillance Program. Jones ME; Jones RN; Sader H; Verhoef J; Acar J J Antimicrob Chemother; 1998 Jul; 42(1):119-21. PubMed ID: 9700544 [No Abstract] [Full Text] [Related]